141 related articles for article (PubMed ID: 35644299)
1. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
Zhang K; Huang L; Lai F; Lin S; Tian H; Wu D; Chen X; Xu H
Bioorg Med Chem Lett; 2022 Sep; 71():128825. PubMed ID: 35644299
[TBL] [Abstract][Full Text] [Related]
2. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Li J; Qian C; Zhou Q; Li J; Li K; Yi P
Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
[TBL] [Abstract][Full Text] [Related]
3. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
4. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11.
Imai H; Saijo K; Chikamatsu S; Kawamura Y; Ishioka C
Cancer Sci; 2021 Feb; 112(2):792-802. PubMed ID: 33274548
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.
Saijo K; Imai H; Chikamatsu S; Narita K; Katoh T; Ishioka C
Cancer Sci; 2017 Jul; 108(7):1469-1475. PubMed ID: 28406576
[TBL] [Abstract][Full Text] [Related]
6. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
Saijo K; Katoh T; Shimodaira H; Oda A; Takahashi O; Ishioka C
Cancer Sci; 2012 Nov; 103(11):1994-2001. PubMed ID: 22924958
[TBL] [Abstract][Full Text] [Related]
7. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
[TBL] [Abstract][Full Text] [Related]
8. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.
Wang N; Mo Z; Pan L; Zhou M; Ye X; Liu X; Cai X; Qian C; Chen F; Xiong Y; Fan F; Li W
Target Oncol; 2023 Nov; 18(6):941-952. PubMed ID: 37855991
[TBL] [Abstract][Full Text] [Related]
10. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Mondello P; Derenzini E; Asgari Z; Philip J; Brea EJ; Seshan V; Hendrickson RC; de Stanchina E; Scheinberg DA; Younes A
Oncotarget; 2017 Feb; 8(8):14017-14028. PubMed ID: 28147336
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Lemm EA; Valle-Argos B; Smith LD; Richter J; Gebreselassie Y; Carter MJ; Karolova J; Svaton M; Helman K; Weston-Bell NJ; Karydis L; Williamson CT; Lenz G; Pettigrew J; Harwig C; Stevenson FK; Cragg M; Forconi F; Steele AJ; Cross J; Mackenzie L; Klener P; Packham G
Clin Cancer Res; 2020 Apr; 26(7):1700-1711. PubMed ID: 31831562
[TBL] [Abstract][Full Text] [Related]
13. Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
Park E; Lee C; Park J; Liu J; Hong J; Shin DY; Byun JM; Yun H; Koh Y; Yoon SS
Leuk Lymphoma; 2023 Jan; 64(1):205-216. PubMed ID: 36331521
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
[TBL] [Abstract][Full Text] [Related]
15. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
16. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
17. Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.
Kim SJ; Kim UJ; Yoo HY; Choi YJ; Kang KW
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575557
[TBL] [Abstract][Full Text] [Related]
18. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
Uddin S; Hussain AR; Siraj AK; Manogaran PS; Al-Jomah NA; Moorji A; Atizado V; Al-Dayel F; Belgaumi A; El-Solh H; Ezzat A; Bavi P; Al-Kuraya KS
Blood; 2006 Dec; 108(13):4178-86. PubMed ID: 16946303
[TBL] [Abstract][Full Text] [Related]
19. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
20. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia.
Zhang K; Huang R; Ji M; Lin S; Lai F; Wu D; Tian H; Bi J; Peng S; Hu J; Sheng L; Li Y; Chen X; Xu H
Eur J Med Chem; 2024 Jan; 264():116015. PubMed ID: 38048697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]